Sevirumab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | CMV |
Clinical data | |
ATC code |
|
Identifiers | |
ChemSpider |
|
(verify) |
Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]
References
- ^ Borucki, MJ; Spritzler, J; Asmuth, DM; Gnann, J; Hirsch, MS; Nokta, M; Aweeka, F; Nadler, PI; et al. (2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
{{cite journal}}
: CS1 maint: numeric names: authors list (link) - ^ ClinicalTrials.gov